Vita means life. It's also our platform for sharing the stories of biotech's promise to patients and public health.
CSL consists of CSL Behring, CSL Seqirus and CSL Vifor. Learn more by visiting each section.
Biotechnology leader CSL Behring offers the broadest range of quality plasma-derived and recombinant therapies in our industry.
Derived from the expression 'securing health for all of us', CSL Seqirus is one of the world's largest influenza vaccine providers.
R&D focuses its expertise on four strategic platforms: plasma protein technology; recombinant technology; cell and gene therapy; and vaccines technology.
One of our core values at CSL is Innovation. We support collaborative innovation through the endowment of awards and grants to researchers around the world.
As part of our broader sustainability strategy to build a more sustainable future, we've committed to a 40% reduction in absolute Scope 1 and 2 emissions by 2030.
Along with our sustainability strategy, CSL’s community contribution framework helps deliver on our Values and support execution of our 2030 strategy.
At CSL, Diversity, Equity, and Inclusion (DEI) is at the core of our mission and who we are. It fuels our innovation day in and day out.
Whether you are early in your college education or recently completed your degree, it's never too soon to consider CSL for your Promising Future!
Even prior to the Omicron variant, U.S. experts urged four COVID-19 shots for this group after research found the vaccines pr…
Health officials recommend getting vaccinated against seasonal influenza, but do you know why? For one thing, the flu is alwa…
To make manufacturing smarter, a pilot plant in Australia is exploring how to replace paper with next-generation technology.
Around the world, specialized units inside hospitals take on the most severe injuries and act fast to save lives.
We discuss ethical questions with expert Hervé Chneiweiss, who serves on the World Health Organization (WHO) committee that’s…
Before you try to help, learn these dos and don’ts.
In an update, immunologist says most PID patients appear no more at risk than the general population.
CSL Behring’s plasma-collection arm marks a milestone with the opening of a new center in Florida.
Learn why early diagnosis and treatment for Alpha-1 Antitrypsin Deficiency is important.
Americas
Asia Pacific
Middle East
Europe